Bioneeds India Private Limited – FDA 483, Jan 19, 2024

An FDA inspection of Bioneeds India Private Limited, a contract testing laboratory in Bangalore Rural, India, was conducted from January 15-19, 2024, resulting in a Form FDA 483. The inspection identified three key observations indicating deficiencies in laboratory control and adherence to established procedures.

Firstly, the firm demonstrated inadequate evaluation of laboratory deviations during method validation for *in vitro* bioassays. Issues included unmet assay linearity acceptance criteria and uninvestigated failures in reference standard potency system suitability. This indicated a lack of robust root cause analysis and impact assessment on method suitability.

Secondly, written procedures and actual investigations into assay failures were found to be inadequate. The Standard Operating Procedure (SOP) for investigating failures lacked clear requirements for repeat testing and experimental hypothesis testing. Additionally, an investigation into system suitability failures for drug product batches lacked scientific justification for the identified root cause and failed to outline corrective actions.

Finally, the inspection revealed that validated test methods were not consistently followed. Specifically, the incubation time for a relative potency bioassay was observed to deviate from the approved SOP and procedures submitted to the FDA, raising concerns about data integrity and consistency.

These observations indicate that Bioneeds India Private Limited must implement comprehensive corrective actions to address these deficiencies and ensure compliance with regulatory expectations for a contract testing laboratory.